Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study.

Olga MontvidaSubodh VermaJonathan E ShawSanjoy K Paul

Published in: Diabetes, obesity & metabolism (2020)

While the effectiveness of SGLT2 inhibitors was similar among black and white patients, irrespective of ASCVD status, black patients continued to have worse cardiometabolic risk factor burden after SGLT2 inhibitor initiation.

Keyphrases

end stage renal disease
risk factors
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
randomized controlled trial
systematic review
peritoneal dialysis
patient reported outcomes